Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia  | Date: 2021-04-06

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical trials displayed promising outcome.

The pharmaceutical firm said that in its Phase 3 trials, more than 91.15% of patients administered with PegIFN PegiHepTM, had an RT-PCR negative result by the seventh day, in comparison to 78.90% of patients treated with SOC (standard of care) arm.

In the case of moderate COVID-19 patients, the medication decreased the period of additional oxygen from 84 hours to 56 hours. This shows that it was able to manage respiratory distress and failure, which has been one of the most difficult aspects of managing COVID-19, the company added.

It is worth noting that the drug has a well-established record of safety, with several doses being given to chronic hepatitis B and C patients for several years.

Aging decreases the ability of the body to generate Interferon Alpha which helps in responding to viral infections, further increasing the risk of death among elderly individuals. Pegylated Interferon Alpha 2b, provided at an early stage of the infection, can compensate for this deficiency and speed up recovery.

The preliminary findings suggest that, if given early, PegIFN can help in faster recovery of patients and prevent many of the problems seen in later stages of the disease. Since it is a single-dose regimen, the treatment would be less difficult and more affordable, Zydus said.

Dr. Sharvil Patel, Managing Director at Cadila Healthcare Ltd., reportedly said that they are motivated by the Phase III results of the PegIFN study which has shown the potential to decrease the impact of the virus when given in the early stage of the disease.

In addition to performing a Phase-II trial in Mexico, the company is collaborating with the USFDA on Pegylated Interferon clinical trials in the United States, sources with relevant information cited.

Source Credit –

https://www.businesstoday.in/current/corporate/zydus-covid-19-drug-shows-promise-phase-3-trials-seeks-dcgi-nod/story/435729.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Zomato net loss triples to USD 46 million despite 75% jump in revenues

Zomato net loss triples to USD 46 million despite 75% jump in revenues

By Nikita Chaurasia

Indian food delivery giant Zomato Limited has reported a net loss worth USD 46 million in Q4 of FY2021-22 despite witnessing a 75% growth in revenue to USD 156 million as opposed to USD 89 million it earlier recorded during the fourth quarter of the ...

Facebook-owner Meta to share more data on political advertisements

Facebook-owner Meta to share more data on political advertisements

By Nikita Chaurasia

Facebook-parent Meta Platforms Inc has recently announced that it would provide additional data from its public ad database regarding the targeting decisions made by publishers running social and political-issue advertising. As a part of the expan...

Massachusetts finds first 2022 monkeypox case in the United States

Massachusetts finds first 2022 monkeypox case in the United States

By Nikita Chaurasia

The Massachusetts Department of Public Health has recently reported the first case of a rare infection called monkeypox in a man who recently visited Canada. According to Boston’s public department, the identified case is no threat to the pu...

Russia denies plans of blocking YouTube & cutting off from the internet

Russia denies plans of blocking YouTube & cutting off from the internet

By Nikita Chaurasia

The Digital Development Minister of Russia has reportedly stated that the country is not planning to block Google’s video streaming platform YouTube as such a move would affect its users and will therefore be avoided.  It is worth notin...

Indian food delivery giant Swiggy to buy Dineout from Times Internet

Indian food delivery giant Swiggy to buy Dineout from Times Internet

By Nikita Chaurasia

Swiggy, an Indian food delivery giant, has recently announced an agreement with Times Internet to buy Dineout, a dining and restaurant technology platform. Swiggy will use the acquisition to enter the dining out (non-delivery) market, where it will c...